Nivolumab-related mucous membrane pemphigoid
Dermatologic immune-related adverse events (IRaes) are among the most frequent toxicities reported with anti –programmed cell death (PD)-1 or anti–programmed cell death ligand (PD-L1) therapies, affecting up to 40% of treated patients [1,2]. They have been associated with a variety of dermatologic manifestations including eczema-like rash, pruritus, lichenoid reactions, induction or reactivation of pre existing psoriasis, vitiligo and granulomatous reactions [3]. They may also induce or reactivate autoimmune skin diseases [4].
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Vincent Sibaud, Emmanuelle Vigarios, Aurore Siegfried, Chloe Bost, Nicolas Meyer, Cecile Pages-Laurent Tags: Letter to the Editor Source Type: research
More News: Autoimmune Disease | Cancer | Cancer & Oncology | Dermatology | Eczema | Pemphigoid | Psoriasis | Skin | Toxicology | Vitiligo